- Home
- CCCC
CCCC
C4 Therapeutics Inc.
as 11-21-2025 3:41pm EST
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 242.3M | IPO Year: | 2020 |
| Target Price: | $8.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.08 - $5.10 | Next Earning Date: | 11-06-2025 |
| Revenue: | $30,108,000 | Revenue Growth: | -10.57% |
| Revenue Growth (this year): | -19.5% | Revenue Growth (next year): | -18.28% |
Latest C4 Therapeutics Inc. News
CCCC Breaking Stock News: Dive into CCCC Ticker-Specific Updates for Smart Investing
![[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)](/cdn/transform/width=500,quality=90,format=webp/https://cdn.finquota.com/news/12bacf83-7fff-4961-878a-ab1569e302d2.png)
GlobeNewswire
5 days ago
[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)
Zacks
16 days ago
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates
GlobeNewswire
16 days ago
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Zacks
18 days ago
Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates
MT Newswires
a month ago
C4 Therapeutics Prices $125 Million Underwritten Offering; Shares Fall Pre-Bell
GlobeNewswire
a month ago
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
Simply Wall St.
2 months ago
Spotlight On Aware And 2 Other Promising Penny Stocks
Zacks
7 months ago
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
Compare CCCC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CCCC C4 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.